Group 1 - The company, Zhongji Changshou Science (00767), has signed a non-binding memorandum of understanding to acquire 100% equity of the target company, Comprehensive Cell Bank Limited, from China International Orthopedic Medical Group Limited [1] - The target company specializes in cell therapy, cell drug research and development, and health longevity management services, holding the Comprehensive Cell Bank [1] Group 2 - Comprehensive Cell Bank is the world's largest international autologous immune cell bank and is recognized for meeting various international standards, including FDA, AABB, and PIC/S cGMP [2] - It is the only clinical cell bank in Asia registered with the FDA for both immune cells and stem cells, ensuring compliance with international standards for cell management [2] Group 3 - The Comprehensive Cell Bank began operations on November 17, 2018, and possesses patented technologies in cancer early screening, NK cells, stem cells, and cartilage cells, along with 22 advanced medical testing platforms [3] - The company can provide services to 300,000 people globally, with potential revenue exceeding HKD 30 billion from immune cell storage, cancer early screening, longevity medical testing, and related cell therapies [3]

格隆汇8月4日丨中基长寿科学(00767.HK)公告，于2025年8月4日，公司（买方）与中国国际骨关节医疗 集团有限公司（卖方）订立一项不具法律约束力谅解备忘录，据此，买方拟收购（由其本身或透过其全 资附属公司）而卖方拟出售亚洲综合细胞库有限公司（目标公司）股权总额的100%。 亚洲综合细胞库是亚洲唯一美国FDA注册认可的免疫细胞、干细胞双种类全体系国际临床细胞库，是亚 洲唯一ISBER-IRL认证的免疫细胞库，代表亚洲综合细胞库从细胞收集、筛选、检测、包装、处理、储 存、标签到运输都符合美国FDA认可的国际标准，细胞管理在全球处于领先水准。亚洲综合细胞库位于 香港，可储存并合法应用，检测、储存流程和报告由香港卫生署认可的一级或二级医务化验师完成，并 由一级医务化验师独立核实，再由实验室总监双重覆核流程，确保整个过程完全满足或超越本地的法规 要求和安全标准。亚洲综合细胞库已于2018年11月17日开始运营，拥有防癌早筛专利技术、NK细胞专 利技术、干细胞专利技术、软骨细胞专利技术等，拥有22个先进医疗检测平台。基于卖方提供的资料， 可以为全球30万人提供世界领先的免疫细胞储存、防癌早筛、长寿医学检测、健康长 ...